Released Nov 13, 2026, before the open
10-Q filed Nov 13, 2026, 44 days after period end · 0001104659-26-126504
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $963.00K | $0.00 | — | — |
| Net Income | -$25.80M | -$11.92M | -$9.44M | -$15.08M |
| EPS Diluted |
Milestone Pharmaceuticals Inc. · CIK 1408443 · Engraved from SEC EDGAR
| -$0.18 |
| -$0.12 |
| -$0.14 |
| -$0.35 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Net product revenue for CARDAMYST was $1.0 million for Q3 2026, up 73% from the quarter ended June 30, 2026, with approximately 3,400 total prescriptions written since launch.¶1
Cost-efficiency measures are expected to reduce operating expenses by approximately 30%, with approximately $2 million in one-time charges and completion by the first quarter of 2027.¶2¶3
Cash and equivalents of $145.4 million as of September 30, 2026 are expected to provide operating runway into late 2028, more than one year beyond prior guidance.¶4¶5
Net loss for the three months ended September 30, 2026 was $25.8 million, or $0.18 per share, compared with a net loss of $11.9 million, or $0.12 per share, for the prior year period.¶6
An amendment to the Note Purchase Agreement with RTW Investments LP extends the payment-in-kind interest period on its convertible notes from March 31, 2027 to March 2029.¶7